March 2013 Editor's Picks: Products from Weiler Engineering and Pharma Technology Inc. (PTI) - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

March 2013 Editor's Picks: Products from Weiler Engineering and Pharma Technology Inc. (PTI)

Equipment and Processing Report

Featured products from Pharmaceutical Technology's monthly newsletter, Equipment & Processing Report

Weiler Engineering
All-electric, blow–fill–seal machine reduces particulate generation

The all-electric model of the Asep-Tech Model 628 blow–fill–seal machine from Weiler Engineering reduces particulate generation compared to the non-electric model, which is beneficial for parenteral applications. The Model 628 has the flexibility to produce sterile, liquid-filled, tamper-evident containers ranging in size from 0.5 mL up to 500 mL, in full-scale production quantities. A two-piece, stepped-base design allows easy maintenance and convenient product discharge. An integral product buffer tank is designed to meet tight fill tolerances. Additional models are available to fulfill higher output and/or larger container size requirements.

Pharma Technology Inc. (PTI)
System combines tablet deduster, metal detector, and tablet tester on one base

The AIO All-In-One Tablet Deduster and Tester System from Pharma Technology Inc. (PTI) includes PTI’s PharmaFlex segmented deduster spiral, a metal detector, and an in-process tablet tester on one machine base. The tablet tester measures weight, hardness, and thickness at regular intervals and feeds data back to the press where it is recorded and can be used to adjust the process. The tester can be positioned on any of the three sides of the deduster’s base and offers cable-free connections for power and data storage.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Equipment and Processing Report,
Click here